← All trials
NCT05353829
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Apr 29, 2022
- Last posted
- Jul 1, 2022
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Västerbotten County CouncilLead sponsor
- Vastra Gotaland RegionCollaborator
- Danderyds HospitalCollaborator
- Sormland County Council, SwedenCollaborator
- Uppsala UniversityCollaborator
- Uppsala UniversityCollaborator
- Umea UniversityCollaborator
- Karolinska InstituteCollaborator
- County of StockholmCollaborator
- Government of SwedenCollaborator
- Government of SwedenCollaborator
- Government of SwedenCollaborator
- Dalarna County Council, SwedenCollaborator
- Västerbotten County CouncilOverall official - principal investigator
- Västerbotten County CouncilReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.